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ABSTRACT
Citrus fruit and in particular flavonoid compounds from citrus peel have been identified as agents with utility in the treatment of cancer. This review
provides a background and overview regarding the compounds found within citrus peel with putative anticancer potential as well as the associated
in vitro and in vivo studies. Historical studies have identified a number of cellular processes that can be modulated by citrus peel flavonoids
including cell proliferation, cell cycle regulation, apoptosis, metastasis, and angiogenesis. More recently, molecular studies have started to
elucidate the underlying cell signaling pathways that are responsible for the flavonoids’ mechanism of action. These growing data support further
research into the chemopreventative potential of citrus peel extracts, and purified flavonoids in particular. This critical review highlights new
research in the field and synthesizes the pathways modulated by flavonoids and other polyphenolic compounds into a generalized schema. Curr
Dev Nutr 2020;4:nzaa025.
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Medicinal Properties of Citrus Fruits
Citrus fruits such as mandarin, pomelo, orange, lime, lemon, and grape-
fruit have been recognized as having high contents of bioactive com-
pounds (1). Between the pulp and the peel, such fruits contain folate,
vitamin C, dietary fiber, and bioactive compounds such as flavonoids.
Flavonoids are widely distributed in aromatic plants such as mint and
tea but are present in high concentrations in citrus fruits and their
peels (2).
Citrus peel has untapped potential as a source of medicinal com-
pounds because it contains carotenes, essential oils, pectin, and a range
of polyphenolic compounds (3). Epidemiological studies have suggested
that high consumption of fruits and vegetables (>400 g/d) can reduce
cancer risk by ≥20% (4). The Mediterranean diet is rich in fruit pulp and
juice, and the associated high intake of fiber, antioxidants, and polyphe-
nol compounds is linked with a lower cancer risk (5, 6).
The medicinal use of citrus peels can be traced back to the 10th cen-
tury, but the biological activities of specific chemicals within the peel
have only recently been characterized (7, 8). Citrus peels are rich in
polyphenolic compounds, which are secondary plant metabolites with
diverse and essential biological functions (9, 10).
Polyphenolic compounds consist of various classes of bioactive com-
pounds including flavonoids, limonoids, coumarins, phenolic acids, ter-
penoids, tannins, stilbenes, lignans, and carotenoids (11–13). They con-
tain heterocycles including aromatic rings with hydroxyl groups in their
basic structure (14) and exist in the free state or as glycosides. Flavonoids
are likely to be key bioactive compounds in citrus peel, particularly in
terms of their anticancer activity (15–17) as well as in the prevention of
infectious and degenerative diseases (18–20). Although it is appealing to
identify specific molecules with high anticancer activity, there is grow-
ing evidence to suggest synergy between bioactive molecules in citrus
peel extract (CPE). Whole CPEs have been shown to have higher an-
ticancer activity than the fractionated extracts and isolated single com-
pounds. Indeed, the methanolic extracts and freeze-dried CPEs are cor-
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FIGURE 1 Main skeleton of flavonoids and their classes.
Several salient reviews should be noted. Cirmi et al. (4) detail
the range of individual flavonoid and polyphenolic compounds found
within citrus fruits and summarize the preclinical and epidemiologi-
cal evidence for their utility in cancer treatment. Kandaswami et al.
(24) describe the general utility of flavonoid compounds (not specifi-
cally from citrus) in modulating cell signaling pathways. This critical
review focuses on the bioactive compounds that are enriched in cit-
rus peel and examines their underlying mechanism of action. This is
timely based on growing efforts to utilize CPEs as chemopreventive
agents (25), as well as to leverage their antiatherogenic, anticarcino-
genic, anti-inflammatory (26), anticancer (27), antidiarrheal, and an-
timicrobial properties (3, 28). In this extensive field, such studies are
challenging to compare due to a lack of standardized in vitro and in vivo
methodologies, as well as the use of whole CPE compared with indi-
vidual polyphenolics, flavonoids, flavonols, flavones, and polymethoxy-
lated flavones. However, this review explores a range of common mech-
anisms that feature in preclinical studies including motivation of car-
cinogen detoxification, scavenging of free radical species, control of cell
cycle progression, preventing the initiation of cancer, inhibiting cell pro-
liferation, increasing apoptosis, reducing oncogene activity, prohibiting
metastasis and angiogenesis, as well as modulating hormone or growth
factor activity (4, 29–32). This involves highlighting both recent and
historical reports and synthesizing a model for the different biological
functions of CPE bioactives. In most cases there has been no proper
follow-up, either in vivo or in clinical research.
Flavonoid Subtypes within CPE
Flavonoids are low molecular weight compounds that are responsible
for the vivid color of fruit peels, pulp, and leaves (11). They are found
abundantly in citrus fruits, seeds, olive oil, red wine, and tea. More than
9000 flavonoids have been identified to date. Flavonoids feature a basic
C6–C3–C6, 15-carbon skeleton. They are comprised of 2 benzene rings
(A and B), which are linked via a heterocyclic pyran ring (C in Figure 1).
Flavonoids are subdivided according to the presence of an oxy moiety
at C4, a double bond between positions 2 and 3, or a hydroxyl group in
position 3 of a heterocyclic ring (C in Figure 1).
The biological activities of flavonoids increase with the degree of
hydroxylation of the B ring (Figure 1) (24, 33). The basic structure
of flavonoids permits a significant number of substitution patterns in
the benzene rings A and B within each class of flavonoids: O-sugars,
methoxy groups, phenolic hydroxyls, sulfates, and glucuronides (2, 34).
The abundance of distinct flavonoids arises from a large number of dif-
ferent combinations of hydroxyl and methoxyl group substitutions. Be-
sides, flavonoids can be classified by variations of the heterocyclic ring C
to flavones, flavanones, flavonols, isoflavones, flavans, and anthocyani-
dins (9, 35).The antioxidant activity of flavonoids is related to ortho-
dihydroxy substitution in ring B, the presence of a 2,3 double bond and
of a 4-oxo moiety in ring C, as well as a 3-hydroxy-4-keto and/or 5-
hydroxy-4-keto conformation in rings C and A (36, 37).
Flavonoids with a hydroxyl group in position C3 of the C ring are
termed flavonols, and those lacking such an –OH moiety are called fla-
vanones and flavones. Figure 2 illustrates the main structural formu-
las of some flavonoids isolated from CPE and their structural varia-
tions. The main abundant flavonoids in CPE are flavanones such as
neohesperidin, naringin, and hesperidin (38–42) as well as nobiletin,
sinensetin, and tangeretin (43). The biological activities of flavonoids
are related to their antioxidant properties (44). The different degenera-
tive diseases such as brain diseases and Alzheimer disease are affected
by flavonoids via their antioxidant properties (42, 45, 46). There is ev-
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3. R4=H, R3=runose, R2=OH,R1=Me
4. R4=H, R3=runose, R2=R1=H
5. R4=H, R3=runose, R2=OH,R1=H
6. R4=H, R3=neohesperidose, R2=OH,R1=Me




























19. R4=O-runose, R3=H,R2=OMe, R1=OH
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FIGURE 2 The structural formulas of the main citrus peel flavonoids and their subclasses.
idence linking the pharmacological activity of CPE flavonoids to their
ability to reduce the activity of intracellular signaling molecules includ-
ing topoisomerases, phosphodiesterases, and kinases, as well as other
regulatory enzymes (45, 47).
Flavanones (2,3-dihydro-2-phenylchromen-4-one) are a major class
of flavonoids and occur mostly in glycoside forms such as hesperidin,
neohesperidin, narirutin, naringin, eriocitrin, and neoeriocitrin. The
glycosidic forms are divided into 2 types—rutinosides and neohesperi-
dosides. Both rutinose and neohesperidose are glycosylated at position
7 and disaccharides are formed by glucose (Figure 2). The bitter taste
of neoeriocitrin, naringin, and neohesperidin is caused by the pres-
ence of neohesperidose (rhamnosyl-α-1,2 glucose) in flavanones. Hes-
peridin, narirutin, and eriocitrin consist of a flavanone bound to ruti-
nose (rhamnosyl-α-1,6 glucose), and they have no taste. The most crit-
ical flavanones in aglycone forms are naringenin and hesperetin.
Flavonols (3-hydroxy-2-phenylchromen-4-one), such as
kaempferol, quercetin, catechin, and isorhamnetin, are aglycone
forms of flavonoids. Flavonols are recognized by the presence of a
2,3-double bond and the 4-oxo group in the C ring. They differ in
the presence of 1 additional –OH moiety at position C3 in the C
ring. Additionally, the 3-OH group can be glycosylated by different
sugars, which significantly increases the number of flavonol isomers
(48). The glycoside flavonols such as rutin are found in trace amounts
in citrus peel. The predominant types are 3-O-monoglycosides, and
glycosylation occurs at the 3-OH group of the C ring (4).
Flavones (2-phenylchromen-4-one) are found in low concentra-
tions in citrus peel. Nevertheless, they can produce important biolog-
ical activities in vitro and in vivo. For instance, apigenin has shown
high anti-inflammatory activity, and diosmin is an important venotonic
agent (49, 50). Methylated flavones are the key flavones noted in citrus
fruits (51).
Anthocyanidins (2-phenylchromenylium cation) are structurally
derived from pyran, flavan, and flavones found only in grapefruit and
blood oranges (4). Anthocyanidins are the aglycone counterpart of an-
thocyanins that are natural pigments of fruits responsible for the fruits’
and flowers’ violet, red, and blue coloring. The color of the anthocyanin
occurs in response to changes in pH, oxygen, temperature, light, and
enzymes and also by methylation or acylation at the hydroxyl groups
on the A and B rings (52).
Polymethoxylated flavones (PMFs) are a subdivision of flavones
with ≥2 methoxyl groups on their basic benzo-γ -pyrone skeleton and
a carbonyl moiety at the C4 position. Notable PMFs include tan-
geretin, nobiletin, and sinensetin. PMFs exist exclusively in citrus peels
and have been used as herbal (alternative) medicines for decades (49,
53). In research studies, PMFs have shown a broad spectrum of bio-
logical activities including anticarcinogenic (54, 55), antioxidant, car-
diovascular protection, antiproliferation, antiatherogenic (56, 57), and
anti-inflammatory activities (7, 55, 58–60). The permeability of PMFs
through biological membranes is higher than other flavonoids because
of their planar structure and low polarity (58, 61).
The antioxidant, enzyme-inhibitory, and antiproliferative activities
of flavonoids are related to their specific structural features including
the presence of glycosylation, the structure oxidation state, and the
substituents in both the A and B rings of the flavonoid structure (62,
63). Studies of melanoma cell lines employing several flavonoids of
citrus peels have shown the presence of the C2=C3 double bond
on the B ring, conjugated with the 4-oxo function, to be critical for
this biological activity (64). The presence of ≥3 hydroxyl/methoxyl
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groups in each ring (A or B) of the flavonoid skeleton significantly
increased the antiproliferative activity in human melanoma B16F10
and SK-MEL-1 cell lines (64, 65).
Up to 62 glucoside and aglycone limonoids have been reported in
citrus fruits (66). Obacunone glucoside and nomilin acid glucoside are
the major limonoid glucosides in CPEs (67). Coumarins are another
class of bioactive compounds mainly present in citrus peel. Coumarins
such as 7-methoxy-8-(2-oxo-3-methylbutyl) coumarin, 5-geranyloxy-
7-methoxycoumarin, auraptene, limettin, and epoxyaurapten, as well
as furanocoumarins such as psoralen, xanthotoxin, bergamottin, and
epoxybergamottin have been found in citrus peels (68–71). Cinnamic
acids (caffeic, p-coumaric, chlorgenic, ferulic, and sinapic) and ben-
zoic acids (protocatechuic, p-hydroxybenzoic, and vanillic) are pheno-
lic acids found in low concentrations in citrus peel (72, 73). Meanwhile,
carotenes (β-carotene) and xanthophylls [β-cryptoxanthin, lutein, β-
citraurin, violaxanthin, (9Z)-violaxanthin, and zeaxanthin] are the
main carotenoids found mostly in citrus peel (72, 74). Apart from the
above bioactive compounds, d-limonene is the primary essential oil in
citrus peel (75) with anticancer activity in humans (76).
Extraction of Flavonoids from Citrus Waste
In order to maximize the yield of bioactive flavonoid compounds from
citrus peel, several different methods for extraction have been re-
ported in the literature (77). Recommended methods include: 1) chem-
ical methods such as hot water extraction (78, 79), solvent extraction
(80), and alkaline extraction (81, 82); and 2) advanced methods such
as ultrasound-assisted extraction, supercritical fluid extraction (83),
microwave-assisted extraction (84), and enzyme-assisted extraction.
The goal is to develop processes that are rapid and economical.
Most of the pharmaceutical and food industries use solvents for the
extraction of bioactive compounds from citrus. Organic solvents, such
as hexane, methanol, ethanol, petroleum ether, benzene, toluene, ethyl
acetate, isopropanol, and acetone have been used to extract flavonoids
from citrus waste. Phenolic compounds transfer from the solids to the
surrounding solvents during the extraction. The temperature and time
of extraction are specific for different kinds of flavonoids. The limita-
tions of chemical methods are the several hours needed for extraction,
large volumes of solvent, and the extra cost and time to evaporate the
residual solvent. In contrast, “green chemistry” has emerged as a prin-
ciple for the environmentally friendly extraction of high-value com-
pounds. Such methods can be selective, low-energy, time-saving, and
produce higher yields at a reduced solvent consumption (78).
The different extraction methods used for citrus flavonoids have
their own advantages and limitations. However, combined approaches
could ultimately prove superior to any individual method. In gen-
eral, using food-grade solvents and ultrasound-assisted extraction of
flavonoids from citrus waste has a strong potential for future industrial
development as an efficient and environmentally friendly process (85).
Mechanism of Action of CPE Flavonoids
CPEs have been reported to show anticancer activity in various cancer
lines at different efficacious levels; their activity is directly related to the
CPE composition and the cell line sensitivity. The following sections
provide an overview of the in vitro and in vivo studies showing that
CPEs have potential in reducing the risk of cancer development and
progression (Tables 1 and 2).
The following section examines the anticancer effects of CPEs re-
ported in in vitro experiments and animal studies that elucidate the
specific mechanisms involved. The anticancer effect of CPEs can be ex-
hibited through suppression of proliferation, cell cycle inhibition, and
induction of apoptosis.
Suppression of proliferation
Cancer cells differ from normal cells by their ability to proliferate with-
out control, resistance to apoptosis, ability to form new blood vessels,
and metastasis to distant parts of the body. Flavonoids found in CPEs
have been shown to suppress these events through modulation of mul-
tiple cellular proteins that inhibit cell proliferation by downregulation
of oncoproteins.
In human lung carcinoma A549 cells, the methanol extract of Ko-
rean Citrus aurantium fruit peel inhibited cell proliferation dose depen-
dently and also induced apoptosis (86). Similar inhibitory effects were
also observed with flavonoids isolated from Korean C. aurantium peel
in A549 cancer cells (39).
Quercetin—the aglycone form of polyhydroxylated flavonoids
(flavonols) found in onions, berries, grapes, green vegetables, and
apple—is one of the most highly studied flavonoids in terms of its ef-
fects on cell proliferation. It exhibits growth inhibitory effects against
a range of cancer cell lines including immortal human HeLa cells (36),
human epidermoid carcinoma (A431), NK/LY ascites tumor cells, gas-
tric cancer cells including NUGC-2, HGC-27, MKN-28, and MKN-7
(39), colon (COLO 320 DM) (39, 87), human breast (87, 88), human
squamous, gliosarcoma (89, 90), ovarian (91), human pancreatic, and
human liver (HepG2) cancer cells (88, 92). Indeed, quercetin’s strong
antiproliferative effect might be attributable to inhibition of the protein
kinase C (PKC) pathway (93, 94).
Polymethoxylated flavones such as nobiletin, tangeretin, quercetin,
and sinensetin showed antiproliferative activity against human lung car-
cinoma cells (A549), squamous cell carcinoma (HBT43) (90), gastric
cancer, leukemia (HL-60), T-cell leukemia (CCRF-HSB-2), and B16
melanoma cells (95). The antiproliferative effect of naringin is corre-
lated with the inhibition of cell survival by binding ATP on a phospho-
inositide 3-kinase (PI3K) binding site; prohibition of cell growth and
modulation of cell cycle–associated proteins by inhibition of the extra-
cellular signal regulated kinase (ERK)-signaling pathway (96); and/or
binding to p21 to increase the cells’ nuclear antigens and block DNA
synthesis (97). Naringenin and hesperetin exhibited strong antiprolif-
erative activity against a broad spectrum of human [estrogen receptor
positive (ER−)] MDA-MB-435 and (ER+) MCF-7 breast cancer cells,
prostate (DU-145), melanoma (SK-MEL5), lung (DMS-114), and colon
(HT-29) cancer cell lines (60, 90, 98–100).
Nobiletin, a major polymethoxyflavone, also enhances the cytostatic
effect in (ER+) MCF-7 breast cancer cells, via upregulation of inhibitors
selective for the cytochrome P450 family members CYP1B1 and
CYP1A1 (the main oxidizing enzymes which are major determinants
of resistance) (101). Moreover, nobiletin has effectively inhibited the
proliferation of human endothelial cells of human breast, prostate, skin,
and colon carcinoma cells (95, 102); decreased azoxymethane (AOM)-
induced cell proliferation in colonic adenocarcinoma cells (103, 104),
and exhibited direct cytotoxicity in MKN-45, TMK-1, MKN-74, and
KATO-III gastric cancer cells through cell cycle deregulation (105).
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Citrus reticulata D WEHI 3B (<100) — — — — — 106, 107
C. reticulata — SNU-668 (∼100) — — I — — 108
C. sinensis D MCF-7 (10.2–17.9) — — I — — 109






— — I∗ — — 68
17 citrus varieties D HT-29 (31–45) — — — — — 110
C. sunki D HL-60 (25) G2/M — I — — 53
C. aurantium D AGS (40–60) G2/M I I — — 38
C. aurantium — U937 (40–60) — — I I — 111
C. grandis D HeLa (100–200),
AGS (200–400)
— — I — — 70
C. aurantium D A549 (230) G2/M I I — — 39
C. unshiu — MDA-MB-231(>200) — — — I — 112
C. junos — HT-29 (>1200) — — — — I 113
C. aurantifolia — MCF-7 (59) G2/M — I — — 114
C. aurantium D A549 — — I I — 40
C. hassaku D MDA-MB-231 — — — I — 113










— — — — — 115
C. hassaku D SNU-1 (<25) G1 — I — — 116
C. paradisi Kasumi-1 (2000) — — I — — 117
C. reticulata D SKOV3 (∼100) — — I I 118
C. platymamma D A549 (364) G2/M I I — I 86
C. sphaerocarpa D MDA-MB-231
(>200)
— — — I I 113







— I∧ I∧ I∧ I∧ 75
C. platymamma D Hep3B (100–200),
HepG2 (300–400)
G2/M I# I# I# — 119
C. sinensis D HepG2 (>500) G1 I I — — 120
C. reticulata — HCT116 — — — — — 121
1D, determined; I, induced; ∗only for U937; ∧only for DU145; #only for Hep3B.
Cell cycle dysfunction is correlated with cancer development. Cell
cycle progression is a complex and highly regulated process and con-
sists of 4 phases: G1, S, G2, and M (122). The progression of cells from
one phase to another is controlled by the coordinated interaction of
cyclin-dependent kinases (CDKs) and their cyclin subunits to form ac-
tive complexes. The formation of an active complex is regulated by CDK
inhibitors. In normal cells, cell cycle progression is arrested when faulty
DNA needs to be repaired, or further cell replication is not required.
In the context of cancer, by arresting the cell cycle progression of ma-
lignant cells the tumor or metastatic cancer burden can be reduced or
eliminated (123, 124).
CPEs can modulate proteins involved with cell growth such as
epidermal growth factor receptor and reticular activating system
(Ras), which have a range of downstream pathways including mitogen-
activated protein kinases (MAPKs), serine specific protein kinase (Akt),
3-kinase PI3K/Akt, and mechanistic target of rapamycin (mTOR).
Methanol extract from freeze-dried Korean C. platymamma flavonoids
reduced the proliferation of Hep3B cells by inhibiting PI3K and Akt
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phosphorylation and increased the ERK1/2, c-Jun N-terminal kinase,
and p38 MAPK phosphorylation; these reduced PI3K/AKT signaling
and increased MAPK activity (119). Methanol extract of the peel of C.
aurantium also suppressed the phosphorylation of Akt in U937 cells
(111), and mTOR in SNU-1 cancer cell lines (116). In A549 cells, the
ethanolic extract from C. aurantifolia peels inhibited cell proliferation
dose dependently while inducing apoptosis (39, 86, 114). The suppres-
sion of growth signals was ascribed to Akt, Ras, ERK1/2, and E-cadherin
in colon tumor-bearing mice (125). The treated mice showed low con-
centrations of inactive glycogen synthase kinase-3β and low accumu-
lation in cell nuclei of β-catenin, which limits the activity of signaling
pathways. The oral administration of CPEs from Gold Lotion has been
reported to considerably reduce the enzyme ornithine decarboxylase,
which controls cell growth and proliferation through the biosynthesis
and metabolism of polyamines in treated mice with colorectal cancer
(125–127).
Cell cycle inhibition
CPEs suppress cancer cell proliferation by arresting cell cycle progres-
sion and modulating cell proliferation signaling pathways that can be
reduced or eliminated in malignant cells. Analysis of cell cycle distribu-
tion in CPE-treated cells demonstrated that auraptene, the main com-
pound of the supercritical fluid extraction of C. hassaku Hort ex. Tanaka
peel, caused cell cycle arrest mainly at G1 phase (116, 120). The ethanoic
extract of C. aurantifolia lime peels at a concentration of 6 μg/mL in-
duced apoptosis and cell accumulation at G1 phase, whereas the 15-
μg/mL extract induced apoptosis and cell accumulation at G2/M phase
(38, 39, 86, 119, 114). CPEs have been shown to upregulate the ex-
TABLE 2 In vivo anticancer effects of citrus peel extract1
Sample Animal models Dose (route) Duration Effects Reference
Citrus junos HT-29 cells implanted mice 100 mg/kg/d (i.p.) 4 wk Reduced tumor size,
disease activity index and
colon shortening
113
C. aurantium A549 cells injected in mice
tail vein
Twice weekly (i.p.) 5 wk Reduced cancer metastasis 40
C. reticulata Treated leukemic cells
injected into mice
— 2/10 wk Reduced number of tumor





0.2% in diet 26 wk Reduced number and size
of ACF, tumor burden,
and incidence
128
C. sinensis Western diet inducing
cancer






100/200 μL twice weekly
(cream application)






C. unshiu Double-TPA application to
ICR mouse skin
8.1 nmol/30 min 24 h Inhibit NO and O2−
generation
56
Multiple citrus PC-3 cells implanted in
mice
1/2 mg/kg 5 d/wk (i.p.) and
2 or 4 mg/kg 5 d/wk (o.p.)
3 wk Suppressed tumor size 126
Multiple citrus AOM-induced
carcinogenesis in mice
100/200 μL 5 d/wk (o.p.) 6 wk Reduced number of ACF 126
C. iyo DU145 cells implanted in
mice
50/200 mg/kg thrice weekly
(i.p.)
4 wk Suppressed tumor growth 75




100 μL of 10%/d 1 wk Reduce photoaging in mice 130
C. sinensis HepG2 cells implanted in
mice
1/10 mg/kg thrice weekly in
diet
3 wk Reduced tumor growth 120
C. sinensis AOM-induced
carcinogenesis in mice
0.01/0.05% in diet 4/18 wk Reduced number of ACF 125
1ACF, aberrant crypt foci; AOM, azoxymethane; DMBA, 7,12-dimethylbenz(α)anthracene; ICR, Institute of Cancer Research; i.p., intraperitoneal injection; o.p., oral
injection; TEWL, transepidermal water loss; TPA, tissue plasminogen activator.
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pression of p21 (cyclin-dependent kinase inhibitor 1) and/or p53 (tu-
mor suppressor protein) leading to G1 arrest as observed in breast can-
cer cell line MCF-7 (114), human gastric cells SNU-1 (116), DU145
prostate cancer cells (75), and COLO 205 human colon carcinoma cells
(114, 131). The CPEs can also arrest cell cycle at G2/M by increas-
ing the expression of p21 and decreasing the expression of cyclin B1,
cell division cycle 25C (CDC25C), and CDC2 in A549, Hep3B, and
human gastric cancer AGS cells (38, 39, 86, 119). A water-based ex-
tract from C. sinensis L. peel (which chiefly contains hesperidin and
narirutin) modulated the cell cycle of quiescent (PC-3 and LNCaP)
prostate cancer cells, impairing their ability to enter the S phase (2–3%
reduction of G0/G1 cells compared with 12–18% reduction of control
cells) (132).
Tangeretin induced G1 phase by increasing the expression of p37
and p21 in COLO 205 human colon carcinoma cells (131) and pro-
hibited the growth of estradiol-stimulated T47D cells (133). Nobiletin
modulated the cell cycle in MKN-45, TMK-1, and KATO-III human
gastric carcinoma cells (105), and MKN-74, and induced G1 phase ar-
rest in MCF-7 and MDA-MB-435 breast cancer cells, and HT-29 colon
cancer cell lines (134, 135). Hesperetin decreased the activity of MCF-
7 breast cancer cells by accumulating cells in G1 phase through the
inhibition of CDK4, CDK2, and cyclin D, upregulation of p21
and p27, and increased binding of p21 and CDK4 (136). Both
tangeretin and nobiletin led to the accumulation of cells in the
G1/S cell cycle in human colon and breast cancer cells. Naringin
induced G1 arrest by upregulation of p21 (96). Apigenin also
arrested cell cycle in G2/M phase in both androgen-insensitive
PC-3 and androgen-sensitive LNCaP human prostate cancer cell
lines by activation of a cyclin kinase suppressor WAF1/p21 (137)
(Table 3).
Induction of apoptosis
Apoptosis and necrosis are 2 distinct mechanisms of cell death in eu-
karyote cells. Apoptosis, or programmed cell death, is involved in em-
bryonic development, hormone-dependent atrophy, and metamorpho-
sis. These processes eliminate damaged or unwanted cells (138). The
apoptosis is characterized by plasma blebbing, cell shrinkage, and frag-
mented nuclei/DNA (139), which are reported in a variety of cancer cells
treated with CPE in vitro (38, 40, 42, 53, 68, 70, 75, 111, 116, 119, 117)
and in an in vivo mouse model (140).
Citrus peel polymethoxyflavones and CPE from C. unshiu in-
duce apoptosis mainly through the intrinsic pathway by reducing an-
tiapoptotic B-cell lymphoma 2 (Bcl-2) and B-cell lymphoma extra
large (Bcl-XL) proteins and increasing proapoptotic proteins [Bcl-
2 associated X protein (Bax); proapoptotic Bcl-2 protein (Bid); Bcl-
2 homologous antagonist killer (Bak); Bcl-2-associated death pro-
moter (Bad)] in different cancer cell lines (105, 141–143). The in-
crease in the ratios of Bax/Bcl-XL and Bax/Bcl-2 allows the release
of cytochrome c through the permeabilized mitochondrial membrane.
Following the binding of cytochrome c to the apoptosis protease–
activating factor 1 and formation of an apoptosome complex, ac-
tivation of caspase-9 and the apoptosis effector protein caspase-3
is achieved (144).
Increase of caspase-9 and caspase-3 was reported following treat-
ment with CPEs (super critical extract of C. hassaku peels) for many
cancer lines including gastric carcinoma SNU-668 (108) and SNU-1
(116), adenocarcinoma human alveolar basal epithelial cells A549 (40,
86), histiocytic lymphoma U937 (68, 111), metastatic prostate can-
cer DU145 (75), human gastric cancer AGS (38), hepatocellular car-
cinoma Hep3B (119) and HepG2 (120), as well as acute myeloblas-
tic leukemia Kasumi-1 (Citrus × paradisi Macfad.) (125, 117). CPEs
increased the concentrations of cleaved poly ADP-ribose polymerase
inhibitors in U937, SNU-1, AGS, Kasumi-1, A549, Hep3B, DU145,
and colon cancer cells (38, 68, 75, 86, 111, 116, 119, 125, 117).
CPE can also reduce endogenous inhibitor of apoptosis (IAP) proteins
such as XIAP, cIAP1, and cIAP2 in U937 (111) and DU145 cancer
cells (75).
It was reported that nobiletin could induce apoptosis by increasing
Bax and p53 protein expression, inhibiting Bcl-2 protein expression, and
elevating the ratio of Bax/Bcl-2 proteins in human lung A549 adeno-
carcinoma cells (145). Tangeretin induced apoptosis in leukemia HL-
60 cells by affecting the mitogen-stimulated blastogenic response of hu-
man peripheral blood mononuclear cells (99), and quercetin promoted
apoptosis as a consequence of cell cycle arrest in triple-negative breast
cancer cells (88, 92, 146).
Accumulated evidence supports that CPE has negligible apoptosis-
inducing effects through the extrinsic apoptotic pathway. It was
shown that CPEs induced apoptosis in U937 cells by increasing
caspase-8; however, expression of the death receptors [DR4, DR5,
and Fas (a receptor protein of the TFN family)], and proapop-
totic ligands such as TFN-related apoptosis-inducing ligand (TRAIL),
Fas ligand (FasL), and Fas-associated protein with death domain
(FADD) was unchanged (111). Similarly, no reduction in the Fas
and FasL proteins was observed in Hep3B cells treated with CPE
(119). Further research is required to clarify the precise modula-
tion of extrinsic apoptotic pathways involving cell death receptors by
CPEs.
Inhibition of angiogenesis
It is well established that tumor growth is dependent on angiogenesis—
the growth of new blood vessels around cancer tissue needed to supply
nutrients and oxygen to tumor cells (147). Because angiogenesis is
essential for the growth of different cancers, vascular targeting has
been considered as a potential strategy to reduce tumor growth and
metastasis.
Flavonoids are antiangiogenic through a variety of mechanisms:
they inhibit vascular endothelial growth factor (VEGF) expression,
suppress endothelial cell migration, and decrease matrix metallopro-
teinases MMP-2 and MMP-9 (148).
The antiangiogenic properties of quercetin include inhibition of
MMP-2 and MMP-9 secretion from tumor cells as well as inhibition of
endothelial cell proliferation and migration (149). Quercetin reduced
tube formation of VEGF-stimulated human umbilical vein endothelial
cells (HUVECs) by 40% in vitro (150). Luteolin and apigenin are the
most potent angiogenesis inhibitors, acting by inhibiting the release of
inflammatory cytokine IL-6 and the signal transducer and activator of
transcription 3 (STAT3) pathway (149). Hydroxylated PMFs suppress
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the expression of MMPs and VEGF in colonic tumors. For example,
sinensetin inhibited angiogenesis by inducing cell cycle arrest in the
G0/G1 phase in HUVEC culture and downregulated the mRNA expres-
sions of angiogenesis genes kinase insert domain receptor (kdrl), trans-
forming protein p21 (hras), and Friend leukemia integration 1 tran-
scription factor (FLI1) in zebrafish (150). Nobiletin inhibited angiogen-
esis by regulating cell cycle progression through G0/G1 arrest in vivo
(150). It also suppressed CD36 expression and decreased the expres-
sion of thrombospondin 1—an endogenous inhibitor of angiogenesis—
and TGF-β1 (151). Eventually, the expression of VEGF was dramat-
ically modified in DMBA-induced animals by tangeretin treatment
(152).
Inhibition of metastasis
In metastasis, the cancer cells break away from a primary tumor to dis-
tal sites in the body. Metastasis involves several distinct steps including
secretion of metastasis-inducing proteins, cell detachment at a primary
site, migration, adhesion, and invasion at the new site. MMPs such as
MMP-2 and MMP-9 are the main proteins that are necessary for metas-
tasis because they break down the extracellular matrix and allow the
cancer cells to migrate (153).
The antimetastatic effects of CPE extracted by different methodolo-
gies have been tested in a range of cancer cell lines (Table 3). CPEs
have been shown to reduce MMP protein expression and activity in
A549 (40), DU145 (75), Hep3B (119), and MDA-MB-231 breast cancer
cells (154), and in Caco-2, LoVo, and LoVo/ADR colon cancer cell lines
(115). In a notable study, quercetin decreased the invasion of murine
melanoma cells by suppressing MMP-9 via the PKC activator pathway
(155). Genistein prohibited the invasion of triple-negative MDA-MB
231 breast cancer cells in vitro, via downregulation of MMP-9 activ-
ity (153, 155). Apigenin, quercine, and luteolin can also inhibit MMP-2
and -9 activities (156). Flavonoids with an increasing number of substi-
tutions or hydroxyl groups showed a stronger inhibitory effect on the
activity of MMP-9 and -2 (156, 157). Suppression of the MMP proteins
by CPE also was observed in in vivo models for colon (125, 126) and
prostate tumors (140).
Like the reduction in MMPs, CPEs reduced concentrations of
chemokine receptor CXCR4 together with the human epidermal growth
factor receptor 2 (HER2)/neu protein that stimulates CXCR4 expression
in MDA-MB-231 cells (154). CPE also suppressed the phospholipase-
C gamma-1 (PLCG1) protein required for cell migration in U937 cells
(111). Furthermore, vascular cell adhesion molecule-1, which promotes
the adherence of cells at new sites, was reduced by C. unshiu Marc.
peel in MDA-MB-231 cells through inhibition of PKC phosphorylation
(112). Many proteins related to metastasis such as reduced epithelial
mesenchymal transition (EMT) markers (N-cadherin, vimentin, and fi-
bronectin), EMT-associated transcription factors (Slug and Snail), and
activated type I receptors (SMADs) were shown to be downregulated by
the Ougan (C. reticulata cv. Suavissima) flavedo extract in SKOV3 cells
(118).
E-cadherin plays an essential role in cell adhesion, and loss of E-
cadherin is associated with a tendency for tumor metastasis (158). An
increase in the expression of E-cadherin was observed in colon tumor–
bearing mice fed hydroxylated polymethoxyflavones in CPE (125). In
another study, the Korean C. aurantium L. peel showed antimetastatic
properties by preventing the migration and infiltration of A549 cells in
an in vitro experiment (40).
Anti-inflammatory activity
Cancer initiation and proliferation are closely associated with in-
flammation and, in some cases, infection. Inflammation can facil-
itate the initiation and progression of normal cells to malignancy
through the production of inflammatory oxidants such as inducible
nitric oxide synthase (iNOS), myeloperoxidase, eosinophil peroxi-
dase, and NAD(P)H oxidase. Chronic inflammation is associated with
carcinogenesis and acts as a driving force for cancer progression
(159).
The expression of proinflammatory proteins is reduced by CPE in
both in vitro and in vivo models (Table 3). iNOS and inducible-type
cyclooxygenase (COX) are enzymes that are induced in response to
an oxidative environment. Consequently, overexpression of these en-
zymes contributes to carcinogenesis through promotion of inflamma-
tion (7, 56, 136). CPEs downregulated the expression of iNOS and COX-
2 enzymes in human histiocytic lymphoma U937 cell lines, DU145,
and murine macrophage RAW264.7 cells (75, 113, 160–162). Reduc-
tion in these enzymes by CPEs was also observed in colon, skin, and
prostate cancer cell lines in in vivo models (125–127). It is reported that
CPEs in RAW264.7 cells reduced nitric oxide that is produced by iNOS
(163).
NF-κB activation is an essential factor in inflammation. NF-κB is a
heterodimeric protein composed of 5 subunits, and presents in an inac-
tive state in the cytoplasm due to the binding of the inhibitory protein,
IκBα (164, 165). Upon chemical signaling for the activation of NF-κB,
the IκBα degrades and releases the NF-κB from its inactive state in the
cytoplasm. The release of NF-κB allows the translocation of NF-κB sub-
units p50 and p65 to the nucleus, where they activate the transcription of
proinflammatory cytokines, chemokines, adhesion molecules, and en-
zymes. It is documented that CPE treatment reduced NF-κB activation
and the nuclear translocation of its p50 and p65 subunits in RAW264.7,
A549, MDA-MB-231, and U937 cancer cells (125, 113, 160, 161, 163,
121, 166–168).
Likewise, inhibition of NF-κB suppresses a range of downstream
genes that include proinflammatory cytokines. Sweet orange peel ex-
tract with a high amount of PMFs suppressed the expression of
TNF-α, intercellular adhesion molecule 1, IL-1β , IL-6, and IL-8 in
inflammation-induced U937 cells (160). The abundances of TNF-α,
monocyte chemoattractant protein 1 (MCP-1), IL-6, and phosphory-
lated p38 proteins were found to be lower in CPE-treated RAW264.7
cells than the control (113).
CPEs also have a suppressive effect on the STAT3 signaling path-
way, which is involved in inflammation (75, 169). CPEs reduced the
phosphorylation of STAT3 in DU145, PC-3, and prostate cancer cell
line M2182 (75). In the same study, Janus-like kinase and a c-Src ki-
nase that mediated the phosphorylation of STAT3 were also found to
be suppressed by CPE (125).
The mechanism of action of flavonoids on cancer cells
is presented schematically in Figure 3. It is highly complex
and involves not only certain distinct biological processes
but also different modulation of overlapping cell signaling
pathways.
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1Akt, serine specific protein kinase; ANGPT1, angiopoietin 1; AP-1, activator protein 1; Bax, Bcl2-associated X protein; Bcl, B-cell lyphoma; Bcl-xL, Bcl2-associated extra
large protein; BID, a proapoptotic protein; CDK, cyclin-dependent kinase; COX, cyclooxygenase; CREB, c-AMP response element binding protein; CYP, cytochrome P450;
DPPH, 2,2-diphenyl-1-picrylhydrazyl; EGFR, epidermal growth factor receptor; ERK, extracellular signal regulated kinase; Fas, a receptor protein of the TNF receptor family;
flt, vascular endothelial growth factor receptor 1; GSK, glycogen synthase kinase; HIF, hypoxia inducible factor; hras, transforming protein p21; HUVEC, human umbilical
vein endothelial cell; iNOS, inducible nitric oxide synthase; JAK, Janus-like kinase; JNK, c-Jun N-terminal kinase; kdrl, vascular endothelial growth factor receptor kdr-
like; Kip2, cyclin-dependent kinase inhibitor; MAPK, mitogen-activated protein kinase; MEK, mitogen-activated protein kinase kinase; MMP, matrix metalloproteinase;
mTOR, mechanistic target of rapamycin; PgP permeability glyoprotein; PhIP, 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine; PI3K, phosphoinositide 3-kinase; PKC,
protein kinase C; PROM, prominin-1; PTEN, phosphatase and tensin homolog; p21CIP1/WAFI, cyclin-dependent kinase inhibitor 1; P450, cytochrome P450; Raf, a
serine/threonine-specific protein kinase; Ras, reticular activating system; ROS, reactive oxygen species; SNAI, sodium-coupled neutral amino acid transporter 1; STAT,
signal transducer and activator of transcription; TIMP, tissue inhibitor of metalloproteinases; TRAIL, TNF-related apoptosis-inducing ligand; VEGF, vascular endothelial
growth factor; VEGFR, vascular endothelial growth factor receptor.
Functional evidence for citrus anticancer activity in in vivo
models
CPE flavonoids have been suggested to play a critical role in can-
cer prevention and maintaining a healthy lifestyle (207). Individual
flavonoids such as apigenin, nobiletin, hesperidin, and tangeretin,
all highly enriched in CPE, have demonstrated anticancer activity
in preclinical animal models. In addition to single and combined
flavonoids, whole CPE has been tested for anticancer activity in rodent
models.
A series of studies used preclinical mouse models of colon carcino-
genesis to examine the protective effects of crude cold-pressed CPE
oil. This oil contained ∼30% PMFs such as nobiletin, sinensetin, tan-
geretin, and monohydroxylated analogs. When mice were fed a diet
containing 0.2% CPE before, during, and after carcinogen treatment
(128), the number of aberrant crypt foci (ACF)—histological biomark-
ers for colon carcinogenesis—was reduced by 34–66% compared with
the control. The low incidence of tumor development could be due to
the highly potent flavonoids in CPE (102, 128). Feeding mice a diet
containing 0.01% or 0.05% hydroxylated PMFs for 4 wk also reduced
the total number of large ACF and tumors in colonic tissue by 40–44%
compared with controls (125). When mice were fed hydroxylated PMFs
for 20 wk, the number of microadenomas was reduced by ≤81% in
comparison with controls. Similarly, oral administration of CPE with
naringin and hesperidin reduced numbers of ACF by ≤40% compared
with the control group in colon tumor–bearing mice (125). More-
over, the addition of CPE (containing methoxylated flavones, includ-
ing: tetramethoxyflavone, 13.6%; nobiletin, 12.49%; sinensetin, 9.16%;
hexamethoxyflavone, 11.06%; heptamethoxyflavone, 15.24%; and tan-
geretin, 19.0%) at 0.25% or 0.5% to the new Western-style diet reduced
the overall colon tumor number by 26–48% and overall tumor volumes
by 36–63%, and increased the number of apoptotic cells compared with
patients who had the Western-style diet alone (129).
In another study, oral administration of ethanol extract of CPE (C.
junos Tanaka) at 100 mg/kg/d significantly reduced the size of colorectal
adenocarcinoma HT-29 tumor cells through reducing COX-2 expres-
sion in xenograft mice (113). Administration of methanol/water extract
of dried citrus peel (C. reticulata Blanco) at a dose of 1000 ppm in the
diet reduced total ACF by 75% compared with the control (121). In a
similar study, an in vivo model showed that a 70% aqueous methanol
extract of CPE (Korean C. aurantium L.) could prevent human lung
(carcinoma) A549 cells migrating to lungs of mice injected with A549
cells via the tail vein (40). These data suggest that CPE had effects on
the regulation of apoptosis and cell migration.
In a 2-stage skin carcinogenesis model, mice were treated with 7,12-
dimethylbenz(α)anthracene (DMBA) to initiate tumors followed by
repeated application of 12-O-tetradecanoylphorbol-13-acetate to pro-
mote tumor growth. Topical application of CPE, Gold Lotion (the peels
of navel oranges, C. hassaku, C. limon, C. natsudaidai, C. miyauchi, and
satsuma), at 100 μL and 200 μL on the skin reduced the number of pa-
pillomas by 25%, tumor incidence by 18%, tumor weight by 65%, and
the number of tumors with a diameter >5 mm by 33% compared with
controls (127). The epidermal thickening due to the associated inflam-
mation and edema was decreased by 23–33% compared with the control
(127).
Apigenin reduced DMBA-induced skin cancers by inhibiting epi-
dermal ornithine decarboxylase, a key enzyme in cancer prevention
(208). Nobiletin was effective in preventing skin carcinogenesis by sup-
pression of DMBA and 12-O-tetradecanoylphorbol-13-acetate and de-
creasing the inflammatory parameters (56). The daily administration of
hesperidin for 45 days inhibited DMBA-induced experimental breast
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FIGURE 3 Schematic of the main anticancer molecular mechanism of flavonoids. 1. Antiangiogenesis activity via VEGF by inhibiting
HIF-1α/Akt/NF-κB signaling pathways. 2. Anti-inflammation activity by decreasing p38 via MAPK and inhibiting the expression of COX-2.
3. Antimetastasis activity via inhibition of MMP-2/9 by diminishing the Akt/FAK/Ras/PI3K signaling pathways. 4. Antiproliferation activity by
inhibiting PI3K/Akt; via cell-cycle arrest in the G0/G1 or G1/S phase by activating p53 and p21, and also inhibiting BAX and Bcl-2; and by
increasing cytochrome c and activating caspase pathways. Akt, serine specific protein kinase; BAX, Bcl2-associated X protein; Bcl, B-cell
lymphoma; BH3, Bcl-2 homology domain 3; Casp, cysteine-aspartic proteases; cdc, cell division cycle; CDK, cyclin-dependent kinase;
COX, cyclooxygenase; Cyto-C, cytochrome complex; Erk, extracellular signal-regulated kinase; FADD, Fas-associated protein with death
domain; FAK, focal adhesion kinase; FAS, a receptor protein of the TNF receptor family; HIF, hypoxia-inducible factor; IκBα, nuclear factor
of kappa light polypeptide gene enhancer; JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated protein kinase; MMP, matrix
metalloproteinase; mTOR, mechanistic target of rapamycin; PARP, poly ADP-ribose polymerase; PGD2, prostaglandin D2; PGE2,
prostaglandin E2; PGH2, prostaglandin H2; PI3K, phosphoinositide 3-kinase; Ras, reticular activating system; STAT3, signal transducer and
activator of transcription 3; VEGF, vascular endothelial growth factor.
cancer formation through modification of phase I and phase II me-
tabolizing enzymes, as well as modulating the xenobiotic-metabolizing
enzymes during 1,2-dimethylhydrazine-induced colon carcinogenesis
in rats (209). Tangeretin, a PMF, significantly arrested DMBA-induced
breast cancer in rats (210). The anticancer activity of CPE (Gold Lo-
tion) was also tested in prostate cancer models. In PC-3 prostate
tumor–bearing mice, treatment with CPE by intraperitoneal injection of
1 mg/kg/d reduced the tumor weight by 57% and tumor volume by 79%
compared with the control (140, 211). For mice treated with 2 mg/kg/d
by oral ingestion, tumor weight was reduced by 86% and tumor size
by 94%. The strong anticancer activity was attributed to the high con-
centration of PMFs and other compounds such as hesperidin. Chu et al.
(120) showed that the ethyl acetate extracts from sweet orange peel (50–
500 μg/mL) reduced human liver cancer HepG2 growth when tested
in an in vivo model and exhibited significant cytotoxicity on HepG2
cells.
Despite the growing number of preclinical animal studies, clinical
trials involving CPEs are currently limited to a single study. Narin-
genin isolated from C. aurantium peel (Chinese bitter orange) was
tested as a therapeutic on 95 postoperative patients with osteosarcoma
(212). The treatment group (n = 47) that received 20 mg/d of narin-
genin showed significantly reduced osteosarcoma volume compared
with placebo controls.
Conclusions
Citrus fruits are rich in flavonoid compounds; however, much of the
literature to date has focused on the effects of fruit pulp (and juice) con-
sumption rather than examining the rich flavonoid profile of CPE. CPE
is an underutilized commercial resource. For instance, the US orange
juice industry produces 700,000 tons of peel waste annually (213), which
represents nearly 40% of the total weight of the fruit (49). Due to the low
cost and current nonuse of the peel by industry, citrus peel represents an
untapped nutritional source that is rich in bioactive compounds. There
is thus a great deal of potential for the application of citrus fruit peels
to create products that counter the effects of oxidative stress and have
important health benefits (9).
This review has summarized a selection of the key preclinical
and clinical studies that show an anticancer utility for citrus-derived
flavonoids. This property is linked to the chemical structures of
flavonoids, which can dramatically affect a range of molecular and cellu-
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lar mechanisms for inhibiting cancer initiation and progression. Over-
all, citrus flavonoids act not only as free radical scavengers but also as
modulators of several key molecular events implicated in cell survival
and apoptosis. Flavonoids exhibit a remarkable spectrum of biological
activities including anti-inflammatory, anticancer, antiproliferation, an-
tiangiogenesis, antioxidant, cell cycle regulation, and antimetastasis ef-
fects.
Future Studies
Further studies are needed to address in greater detail the basic science
underlying CPE mechanisms, as well as examining pharmacokinetics,
pharmacodynamics, and efficacy in a clinical setting. At a fundamental
level, there is scope to explore the means by which flavonoids enter can-
cer cells and potentially accumulate in specific cellular organelles and
tissues. This plays into the concept of flavonoid bioavailability, and there
has been some discussion regarding innovative methods for enhancing
this property (214). Further study could also focus on elucidating sig-
naling pathways by which CPEs can affect critical enzymes such as ty-
rosine kinases and focal adhesion kinases, PKC, and MMPs.
For clinical translation, trials in both the general population (as
health supplements) and in the setting of cancer treatment are needed
to build upon cell culture studies and preclinical animal models. Mul-
tiple tests indicate that CPEs have a low toxicity profile in vitro and in
vivo, making them suitable for further dietary and food product devel-
opment. Future studies will be required to test the utility of CPEs in a
multitargeted pharmacological strategy, either for cancer prevention or
as a coadministration in oncological therapies.
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